Clinical relevance of a new pre-treatment laboratory prognostic index in patients with oral squamous cell carcinoma

Medical Oncology

Volumn 29, Issue 3, 2012, Pages 1435-1447

  Grimm, M ^a   Lazariotou, M ^b  

^a General Hospital   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Clinicopathological parameters; Oral squamous cell carcinoma; Pre treatment laboratory prognostic index (LPI); Prognostic factors

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CERVICAL LYMPH NODE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE FREE SURVIVAL; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; LABORATORY TEST; LEUKOCYTE COUNT; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUTH SQUAMOUS CELL CARCINOMA; PREDICTIVE VALUE; PRETREATMENT LABORATORY PROGNOSTIC INDEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

AGED; AREA UNDER CURVE; C-REACTIVE PROTEIN; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HEMOGLOBINS; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KAPLAN-MEIER ESTIMATE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; ROC CURVE;

EID: 84872788874     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0045-3     Document Type: Article

References (48)

1. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539-45.
2. Balkwill F, Coussens LM. Cancer: an inflammatory link. Nature. 2004;431(7007):405-6.
3. Apetoh L, Tesniere A, Ghiringhelli F, Kroemer G, Zitvogel L. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res. 2008;68(11):4026-30. doi:10.1158/0008-5472.CAN-08-0427.
4. Grandi C, Alloisio M, Moglia D, Podrecca S, Sala L, Salvatori P, Molinari R. Prognostic significance of lymphatic spread in head and neck carcinomas: therapeutic implications. Head Neck Surg. 1985;8(2):67-73.
5. Greenberg JS, Fowler R, Gomez J, Mo V, Roberts D, El Naggar AK, Myers JN. Extent of extracapsular spread: a critical prognosticator in oral tongue cancer. Cancer. 2003;97(6):1464-70. doi:10.1002/cncr.11202.
6. Sano D, Myers JN. Metastasis of squamous cell carcinoma of the oral tongue. Cancer Metastasis Rev. 2007;26(3-4):645-62. doi: 10.1007/s10555-007- 9082-y.
7. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-7. doi:10.1038/nature01322.
8. Kreppel M, Eich HT, Kubler A, Zoller JE, Scheer M. Prognostic value of the sixth edition of the UICC's TNM classification and stage grouping for oral cancer. J Surg Oncol. 2010;102(5):443-9. doi:10.1002/jso.21547.
9. Tartour E, Deneux L, Mosseri V, Jaulerry C, Brunin F, Point D, Validire P, Dubray B, Fridman WH, Rodriguez J. Soluble interleukin-2 receptor serum level as a predictor of locoregional control and survival for patients with head and neck carcinoma: results of a multivariate prospective study. Cancer. 1997;79(7):1401-8. doi:10.1002/(SICI)1097-0142(19970401)79: 7\1401:AID-CNCR18[3. 0.CO;2-3.
10. Khandavilli SD, Ceallaigh PO, Lloyd CJ, Whitaker R. Serum C-reactive protein as a prognostic indicator in patients with oral squamous cell carcinoma. Oral Oncol. 2009;45(10):912-4. doi: 10.1016/j.oraloncology.2009.03.015.
11. Kruse AL, Luebbers HT, Gratz KW. C-reactive protein levels: a prognostic marker for patients with head and neck cancer? Head Neck Oncol. 2010;2:21. doi:10.1186/1758-3284-2-21.
12. Jablonska E, Piotrowski L, Grabowska Z. Serum levels of IL-1b, IL-6, TNF-a, sTNF-RI and CRP in patients with oral cavity cancer. Pathol Oncol Res. 1997;3(2):126-9.
13. Gallo O, Gori AM, Attanasio M, Martini F, Giusti B, Brunelli T, Gallina E. Interleukin-6 and acute-phase proteins in head and neck cancer. Eur Arch Otorhinolaryngol. 1995;252(3):159-62.
14. Chen HH, Chen IH, Liao CT, Wei FC, Lee LY, Huang SF. Preoperative circulating C-reactive protein levels predict pathological aggressiveness in oral squamous cell carcinoma: a retrospective clinical study. Clin Otolaryngol. 2011;36(2):147-53. doi:10.1111/j.1749-4486.2011.02274.x.
15. Gibson AD, Crawford J, Jain VK. Impact of correction of anemia on clinical outcome in patients with cancer: recent data from head and neck and breast cancer trials. Support Cancer Ther. 2004;1(3):145-9. doi: A1U14R0MK9712G53.
16. Hu K, Harrison LB. Impact of anemia in patients with head and neck cancer treated with radiation therapy. Curr Treat Options Oncol. 2005;6(1):31-45.
17. Dubray B, Mosseri V, Brunin F, Jaulerry C, Poncet P, Rodriguez J, Brugere J, Point D, Giraud P, Cosset JM. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study. Radiology. 1996;201(2):553-8.
18. Lee WR, Berkey B, Marcial V, Fu KK, Cooper JS, Vikram B, Coia LR, Rotman M, Ortiz H. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys. 1998;42(5):1069-75. doi:S0360-3016(98)00348-4.
19. Prosnitz RG, Yao B, Farrell CL, Clough R, Brizel DM. Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 2005;61(4):1087-95. doi:10.1016/j.ijrobp.2004.07.710.
20. Kumar P. Impact of anemia in patients with head and neck cancer. Oncologist. 2000;5(Suppl 2):13-8.
21. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4(7):540-50. doi:10.1038/nrc1388.
22. Lee YJ, Lee HR, Nam CM, Hwang UK, Jee SH. White blood cell count and the risk of colon cancer. Yonsei Med J. 2006;47(5): 646-56. doi:200610646.
23. Grimm RH Jr, Neaton JD, Ludwig W. Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality. JAMA. 1985;254(14):1932-7.
24. Shankar A, Mitchell P, Rochtchina E, Tan J, Wang JJ. Association between circulating white blood cell count and long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Am J Epidemiol. 2007;165(4):375-82. doi: 10.1093/aje/kwk022.
25. Kruse AL, Luebbers HT, Gratz KW. Evaluation of white blood cell count as a possible prognostic marker for oral cancer. Head Neck Oncol. 2011;3:13. doi:10.1186/1758-3284-3-13.
26. Sobin LH, Ch W. UICC. TNM classification of malignant tumors. 6th ed. Berlin: Springer; 2002.
27. Hamilton SR, Aaltonen LA. Pathology and genetics. Tumours of the digestive system. 3rd ed. Lyon: IARC Press; 2000.
28. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;75:457-87.
29. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50(3):163-70.
30. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:1987-2001.
31. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39(4):561-77.
32. Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res. 2009;15(2):425-30. doi: 10.1158/1078-0432.CCR-08-0149.
33. Basso D, Fabris C, Meani A, Del Favero G, Vianello D, Angonese C, Meggiato T, Bellinvia S, Fogar P, Petrin P, et al. C reactive protein in pancreatic cancer and chronic pancreatitis. Ann Clin Res. 1988;20(6):414-6.
34. O'Hanlon DM, Lynch J, Cormican M, Given HF. The acute phase response in breast carcinoma. Anticancer Res. 2002; 22(2B):1289-93.
35. Wang CS, Sun CF. C-reactive protein and malignancy: clinicopathological association and therapeutic implication. Chang Gung Med J. 2009;32(5):471-82. doi:3205/320501.
36. Nozoe T, Korenaga D, Futatsugi M, Saeki H, Maehara Y, Sugimachi K. Immunohistochemical expression of C-reactive protein in squamous cell carcinoma of the esophagus-significance as a tumor marker. Cancer Lett. 2003;192(1):89-95. doi:S03043835 02006304.
37. Jabs WJ, Busse M, Kruger S, Jocham D, Steinhoff J, Doehn C. Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney Int. 2005;68(5): 2103-10. doi:10.1111/j.1523-1755.2005.00666.x.
38. O'Riordain MG, Falconer JS, Maingay J, Fearon KC, Ross JA. Peripheral blood cells from weight-losing cancer patients control the hepatic acute phase response by a primarily interleukin-6 dependent mechanism. Int J Oncol. 1999;15(4):823-7.
39. Wigmore SJ, Fearon KC, Sangster K, Maingay JP, Garden OJ, Ross JA. Cytokine regulation of constitutive production of interleukin-8 and -6 by human pancreatic cancer cell lines and serum cytokine concentrations in patients with pancreatic cancer. Int J Oncol. 2002;21(4):881-6.
40. Bhattathiri VN. Relation of erythrocyte and iron indices to oral cancer growth. Radiother Oncol. 2001;59(2):221-6. doi: S0167814001003267.
41. Overgaard J, Hansen HS, Andersen AP, Hjelm-Hansen M, Jorgensen K, Sandberg E, Berthelsen A, Hammer R, Pedersen M. Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA 2 study. Int J Radiat Oncol Biol Phys. 1989;16(4):1065-8.
42. Vaupel P. Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist. 2008;13(Suppl 3):21-6. doi:10.1634/ theoncologist.13-S3-21.
43. Vaupel P, Hockel M, Mayer A. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal. 2007;9(8):1221-35. doi:10.1089/ars.2007.1628.
44. Schmidt H, Bastholt L, Geertsen P, Christensen IJ, Larsen S, Gehl J, von der Maase H. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer. 2005;93(3):273-8. doi:10.1038/sj.bjc.6602702.
45. Fogar P, Sperti C, Basso D, Sanzari MC, Greco E, Davoli C, Navaglia F, Zambon CF, Pasquali C, Venza E, Pedrazzoli S, Plebani M. Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas. 2006;32(1):22-8. doi:00006676-200601000-00004.
46. Donskov F, von der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol. 2006;24(13):1997- 2005. doi:10.1200/JCO.2005.03.9594.
47. Al-Sarireh B, Eremin O. Tumour-associated macrophages (TAMS): disordered function, immune suppression and progressive tumour growth. J R Coll Surg Edinb. 2000;45(1):1-16.
48. Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem. 2004;279(47):48487-90. doi:10.1074/jbc.R400025200.